{"id":49651,"date":"2025-12-01T22:58:57","date_gmt":"2025-12-01T14:58:57","guid":{"rendered":"https:\/\/flcube.com\/?p=49651"},"modified":"2025-12-01T22:58:58","modified_gmt":"2025-12-01T14:58:58","slug":"ascletis-pharma-advances-asc37-oral-triple-agonist-for-obesity-targets-q2-2026-fda-ind","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49651","title":{"rendered":"Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND"},"content":{"rendered":"\n<p><strong>Ascletis Pharma Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1672:HKG\">HKG: 1672<\/a>) announced it has selected <strong>ASC37 oral tablets<\/strong>, its first <strong>GLP\u20111R\/GIPR\/GCGR triple peptide agonist<\/strong>, as a clinical development candidate and expects to submit an <strong>Investigational New Drug (IND) application<\/strong> to the <strong>U.S. Food and Drug Administration (FDA)<\/strong> for obesity treatment in <strong>Q2\u202f2026<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-preclinical-potency\">Drug Profile &amp; Preclinical Potency<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Receptor Target<\/th><th>ASC37 vs. Retatrutide Potency<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>GLP\u20111R<\/strong><\/td><td><strong>5\u2011fold<\/strong> more potent<\/td><td>Enhanced glycemic control &amp; appetite suppression<\/td><\/tr><tr><td><strong>GIPR<\/strong><\/td><td><strong>4\u2011fold<\/strong> more potent<\/td><td>Improved insulin sensitivity &amp; energy metabolism<\/td><\/tr><tr><td><strong>GCGR<\/strong><\/td><td><strong>4\u2011fold<\/strong> more potent<\/td><td>Increased energy expenditure &amp; fat oxidation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>ASC37 is the <strong>first oral triple agonist<\/strong> to emerge from Ascletis\u2019 proprietary <strong>Peptide Oral Transport ENhancement Technology (POTENT)<\/strong>, designed to overcome oral bioavailability limitations of peptide drugs.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platforms\">Technology Platforms<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>POTENT<\/strong>: Enables oral delivery of large peptide molecules by enhancing intestinal absorption and protecting against enzymatic degradation.<\/li>\n\n\n\n<li><strong>AISBDD (Artificial Intelligence\u2011Assisted Structure\u2011Based Drug Discovery)<\/strong>: Accelerated discovery and optimization of ASC37\u2019s peptide sequence, resulting in superior receptor binding affinity and metabolic stability.<\/li>\n\n\n\n<li><strong>Global IP<\/strong>: Patent filings cover the peptide composition, oral formulation, and therapeutic use in metabolic diseases.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-timeline-amp-regulatory-strategy\">Development Timeline &amp; Regulatory Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Target Date<\/th><th>Scope<\/th><\/tr><\/thead><tbody><tr><td><strong>FDA IND Submission<\/strong><\/td><td>Q2\u202f2026<\/td><td>Obesity indication, US<\/td><\/tr><tr><td><strong>Phase\u202f1 Initiation<\/strong><\/td><td>H2\u202f2026<\/td><td>Safety, PK, PD in healthy volunteers &amp; patients<\/td><\/tr><tr><td><strong>Phase\u202f2a Planning<\/strong><\/td><td>2027<\/td><td>Efficacy signals in obesity; potential expansion to diabetes<\/td><\/tr><tr><td><strong>China Parallel Path<\/strong><\/td><td>TBD<\/td><td>Domestic IND filing under discussion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-competitive-landscape\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Obesity Market<\/strong>: Global market projected to exceed <strong>$130\u202fbillion<\/strong> by 2030; oral therapies expected to capture >60\u202f% share due to patient preference.<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: ASC37\u2019s <strong>oral route<\/strong> and <strong>enhanced potency<\/strong> vs. injectable competitors (retatrutide, tirzepatide) could enable once\u2011daily dosing with superior efficacy.<\/li>\n\n\n\n<li><strong>First\u2011Mover Edge<\/strong>: If approved, ASC37 would be among the first oral triple incretin agonists, positioning Ascletis as a leader in next\u2011generation metabolic therapeutics.<\/li>\n\n\n\n<li><strong>Analyst Outlook<\/strong>: Momentum from <strong>Q2\u202f2026 IND<\/strong> may unlock partnership opportunities with global pharma players seeking oral incretin assets.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding ASC37 development timelines, regulatory submissions, and market potential. Actual results may differ due to clinical, regulatory, and competitive risks.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025113000012_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025113000012_c.\"><\/object><a id=\"wp-block-file--media-30d878e4-b85a-47ba-bbab-3f5befaf603f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025113000012_c.pdf\">2025113000012_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025113000012_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-30d878e4-b85a-47ba-bbab-3f5befaf603f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ascletis Pharma Inc. (HKG: 1672) announced it has selected ASC37 oral tablets, its first GLP\u20111R\/GIPR\/GCGR&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49653,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[189,980,4361,4445,86],"class_list":["post-49651","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-ascletis-pharma","tag-hkg-1672","tag-hot-targets","tag-metabolic-disease","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ascletis Pharma Inc. (HKG: 1672) announced it has selected ASC37 oral tablets, its first GLP\u20111R\/GIPR\/GCGR triple peptide agonist, as a clinical development candidate and expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for obesity treatment in Q2\u202f2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49651\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND\" \/>\n<meta property=\"og:description\" content=\"Ascletis Pharma Inc. (HKG: 1672) announced it has selected ASC37 oral tablets, its first GLP\u20111R\/GIPR\/GCGR triple peptide agonist, as a clinical development candidate and expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for obesity treatment in Q2\u202f2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49651\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-01T14:58:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-01T14:58:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0104.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49651#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49651\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND\",\"datePublished\":\"2025-12-01T14:58:57+00:00\",\"dateModified\":\"2025-12-01T14:58:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49651\"},\"wordCount\":363,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49651#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0104.webp\",\"keywords\":[\"Ascletis Pharma\",\"HKG: 1672\",\"Hot targets\",\"Metabolic disease\",\"Obesity\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49651#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49651\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49651\",\"name\":\"Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49651#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49651#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0104.webp\",\"datePublished\":\"2025-12-01T14:58:57+00:00\",\"dateModified\":\"2025-12-01T14:58:58+00:00\",\"description\":\"Ascletis Pharma Inc. (HKG: 1672) announced it has selected ASC37 oral tablets, its first GLP\u20111R\\\/GIPR\\\/GCGR triple peptide agonist, as a clinical development candidate and expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for obesity treatment in Q2\u202f2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49651#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49651\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49651#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0104.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0104.webp\",\"width\":1080,\"height\":608,\"caption\":\"Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49651#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND - Insight, China&#039;s Pharmaceutical Industry","description":"Ascletis Pharma Inc. (HKG: 1672) announced it has selected ASC37 oral tablets, its first GLP\u20111R\/GIPR\/GCGR triple peptide agonist, as a clinical development candidate and expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for obesity treatment in Q2\u202f2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49651","og_locale":"en_US","og_type":"article","og_title":"Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND","og_description":"Ascletis Pharma Inc. (HKG: 1672) announced it has selected ASC37 oral tablets, its first GLP\u20111R\/GIPR\/GCGR triple peptide agonist, as a clinical development candidate and expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for obesity treatment in Q2\u202f2026.","og_url":"https:\/\/flcube.com\/?p=49651","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-01T14:58:57+00:00","article_modified_time":"2025-12-01T14:58:58+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0104.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49651#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49651"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND","datePublished":"2025-12-01T14:58:57+00:00","dateModified":"2025-12-01T14:58:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49651"},"wordCount":363,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49651#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0104.webp","keywords":["Ascletis Pharma","HKG: 1672","Hot targets","Metabolic disease","Obesity"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49651#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49651","url":"https:\/\/flcube.com\/?p=49651","name":"Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49651#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49651#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0104.webp","datePublished":"2025-12-01T14:58:57+00:00","dateModified":"2025-12-01T14:58:58+00:00","description":"Ascletis Pharma Inc. (HKG: 1672) announced it has selected ASC37 oral tablets, its first GLP\u20111R\/GIPR\/GCGR triple peptide agonist, as a clinical development candidate and expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for obesity treatment in Q2\u202f2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49651#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49651"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49651#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0104.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0104.webp","width":1080,"height":608,"caption":"Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49651#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascletis Pharma Advances ASC37 Oral Triple Agonist for Obesity, Targets Q2 2026 FDA IND"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0104.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49651"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49651\/revisions"}],"predecessor-version":[{"id":49654,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49651\/revisions\/49654"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49653"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}